Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers

References

• Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69:1098–104.
   PubMed Web of Science ®Google Scholar
• Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: data from the 2012 national inpatient sample. CHEST. 2017;151:845–854.
   PubMed Web of Science ®Google Scholar
• Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs. chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307:2383–2389.
   PubMed Web of Science ®Google Scholar
• Levin PA, Dowell JE. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther. 2017;10:2057–2066.
   PubMed Web of Science ®Google Scholar
• Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8:294–301.
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853–865.
   PubMed Web of Science ®Google Scholar
• Kishiro I, Kato S, Fuse D, et al. Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology. 2002;7:93–98.
   PubMed Web of Science ®Google Scholar
• Sack U, Hoffmann M, Zhao XJ, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J. 2005;25:600–604.
   PubMed Web of Science ®Google Scholar
• Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157:1893–1903.
   PubMed Web of Science ®Google Scholar
• Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6:957–965.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843–850.
   PubMed Web of Science ®Google Scholar
• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779–1802.
   PubMed Web of Science ®Google Scholar
• Gremonprez F, Descamps B, Izmer A, et al. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. Oncotarget. 2015;6:29889–29900.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Flynn PJ, Kozloff M, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012;48:1126–1132.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227–1234.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Kubota K, Ando M, et al. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol. 2013;71:457–461.
   PubMed Web of Science ®Google Scholar
• Masago K, Fujimoto D, Fujita S, et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Mol Clin Oncol. 2015;3:415–419.
   PubMedGoogle Scholar
• Tamiya M, Tamiya A, Yamadori T, et al. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol. 2013;30:676.
   PubMed Web of Science ®Google Scholar
• Usui K, Sugawara S, Nishitsuji M, et al. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group trial NEJ013A. Lung Cancer. 2016;99:131–136.
   PubMed Web of Science ®Google Scholar
• Rosell R, Dafni U, Felip E, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017;5:435–444.
   PubMed Web of Science ®Google Scholar
• Jiang T, Li A, Su C, et al. Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients. Oncotarget. 2017 Mar 9. DOI:10.18632/oncotarget.16061
   Web of Science ®Google Scholar
• Su W-C, Lai W-W, Chen HH, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology. 2003;64:18–24.
   PubMed Web of Science ®Google Scholar
• Jones DR, Taylor MD, Petroni GR, et al. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion. J Thorac Oncol. 2010;5:75–81.
   PubMed Web of Science ®Google Scholar
• Chen D, Song X, Shi F, et al. Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. Oncotarget. 2017;8:35262–35271.
   PubMed Web of Science ®Google Scholar
• Jiang L, Li P, Gong Z, et al. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res. 2016;36:1313–1318.
   PubMed Web of Science ®Google Scholar
• Du N, Li X, Li F, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 2013;29:2332–2340.
   PubMed Web of Science ®Google Scholar
• Qi N, Li F, Li X, et al. Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. Medicine (Baltimore). 2016;95:1–8.
   Web of Science ®Google Scholar
• Guo YB, Kalomenidis I, Hawthorne M, et al. Pleurodesis is inhibited by anti-vascular endothelial growth factor antibody. CHEST. 2005;128:1790–1797.
   PubMed Web of Science ®Google Scholar
• Teixeira LR, Vargas FS, Acencio MM, et al. Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis. Lung Cancer. 2011;74:392–395.
   PubMed Web of Science ®Google Scholar
• Massarelli E, Onn A, Marom EM, et al. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. Clin Lung Cancer. 2014;15:379–386.
   PubMed Web of Science ®Google Scholar
• Hsu L-H, Hsu P-C, Liao T-L, et al. Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study. BMC Cancer. 2016;16:463.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184.
   PubMed Web of Science ®Google Scholar
• Sandler A, Hirsh V, Reck M, et al. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer. 2012;78:1–7.
   PubMed Web of Science ®Google Scholar
• Hu P, Liu W, Wang L, et al. High circulating VEGF level predicts poor overall survival in lung cancer. J Cancer Res Clin Oncol. 2013;139:1157–1167.
   PubMed Web of Science ®Google Scholar
• Tamiya M, Tamiya A, Yasue T, et al. Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus carboplatin-paclitaxel treatment for non-small cell lung cancer with malignant pleural effusion. Anticancer Res. 2016;36:2939–2944.
   PubMed Web of Science ®Google Scholar
• Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 2005;353:740–741.
   PubMed Web of Science ®Google Scholar
• Hoyer RJ, Leung N, Witzig TE, et al. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol. 2007;82:409–413.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al.; for the French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–1414.
   PubMed Web of Science ®Google Scholar